FDA grants Isturisa (osilodrostat) expanded indication for the treatment of endogenous hypercortisolemia in patients with Cushing’s syndrome – Recordati
Recordati announced that the FDA has approved the supplemental new drug application (sNDA) for Isturisa (osilodrostat), for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome for… read more.
